An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
about
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphomaRole of the tumor microenvironment in mature B-cell lymphoid malignanciesCurrent challenges and novel treatment strategies in double hit lymphomasThe role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Lymphoma Immunotherapy: Current StatusManagement of mantle cell lymphoma in the elderly patientNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewLymphoma: immune evasion strategiesApproach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryDiffuse large B-cell lymphoma: current strategies and future directionsDiffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.Lenalidomide for the treatment of B-cell lymphoma.Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacySalvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkersActivity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493).A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.Approaches to Managing Safety With Lenalidomide in Hematologic MalignanciesL-PROBe: A Novel Non-anthracycline Combination Chemotherapy Regimen for Aggressive B Cell Non-Hodgkin Lymphoma in Elderly Patients.Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K AxisUpdate on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case reportClinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphomaPrognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.Expanding role of lenalidomide in hematologic malignanciesCC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus?Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis.
P2860
Q24597424-33A7E529-0D39-48E7-A6AC-52421FDB8115Q26738937-5012F2C4-EC43-491E-9115-06902921CF63Q26748775-813E2684-044D-4AF4-8B47-F991E9054F87Q26770385-DE60C15F-DD58-424D-B6E2-1334D5E9D6B4Q26772907-3E1C96A2-1F41-4A7E-B635-1BC9C0B5624AQ26782902-BCABA324-8581-4351-ABD6-CD56A012DEE6Q26999395-F7533C71-407B-493D-B657-C4F5096FAD3BQ27304386-A8A1E2BA-CEA2-456B-B8FA-79E0DCF0D27DQ28080705-9EA16BA8-F49F-4B63-A2BC-7109618E8A05Q28088365-4119DCE9-6B86-4166-BED8-197940EA4810Q28269136-4ECD2A92-7C27-43FE-80E1-2D17934B9F3AQ30235296-ECC838F7-0C6F-4CD9-AEA7-61C193D744F1Q30249007-87B8099E-3EF3-45E0-B01A-37DA84E7AF13Q30358639-F714B41C-13A8-4044-B0F3-BEECD8DB16D4Q30456436-61EB22B8-A3DC-4ED4-89D8-F3C6842C6781Q30659342-0391F067-E144-4C06-8368-2DC14E7A0101Q33398019-E3478AD9-3B4E-458E-83AB-56A5FBF2EB45Q33398415-47002D2E-E5CE-412E-8A11-57B6575AECACQ33399582-0E09F5FB-3018-4BEB-9C7D-28510B5D1901Q33406742-3DD252BF-A2A1-4771-BEE5-01C62AF4077AQ33407102-E2B5A22C-FEA8-4DEC-91EC-11B8AA39DE6AQ33408772-8507D59F-FC06-495C-8528-2025927FD29EQ33410282-BAAC1401-B154-4EE0-AE1C-F997A65E2365Q33413210-B8290E5A-5541-4B1F-8AAC-6824325300B6Q33416550-F53A08D2-75BB-4644-9B64-0D706BD3D837Q33416695-5B61BE62-FF37-46D2-80B7-CF8BD4EE17EEQ33418964-3E87440D-6C14-4E56-A4B4-490F5BE9E62AQ33421147-4FFCD8D9-E209-4E27-B47C-C969B331BDD8Q33423873-3CC372E7-9DD9-47BA-BF7B-57200A9D3878Q33439291-2EA4D1F2-29B5-4487-92A2-10BEF640963BQ33817800-5A2E2CEA-CB6C-4675-BD56-25D9D2B68C73Q34253548-C17489DF-F3FC-4482-9A62-43A132B16CAEQ34314074-06B53276-2FE0-42C2-88D2-75E30C3DE199Q34365673-E4425A4B-5407-448D-B1DB-72BFADD12F5EQ34819534-957CD4B3-8283-46A5-B7DA-2C1176A3FB28Q34882773-9717D11C-52FB-47E7-89EC-8878FCA9D7F8Q35592305-E9B1393A-F00B-4CF5-98EB-AE1B7607DCF3Q35640007-03B58ED6-56B2-4291-99C3-78E34D180DD0Q35835983-1D6EEAC9-C705-4C3E-8F78-6113AECEDCE2Q36046230-CA7661D5-3B73-412C-9DEE-D37C1A3A5BBE
P2860
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
An international phase II tria ...... B-cell non-Hodgkin's lymphoma.
@ast
An international phase II tria ...... B-cell non-Hodgkin's lymphoma.
@en
type
label
An international phase II tria ...... B-cell non-Hodgkin's lymphoma.
@ast
An international phase II tria ...... B-cell non-Hodgkin's lymphoma.
@en
prefLabel
An international phase II tria ...... B-cell non-Hodgkin's lymphoma.
@ast
An international phase II tria ...... B-cell non-Hodgkin's lymphoma.
@en
P2093
P2860
P356
P1433
P1476
An international phase II tria ...... B-cell non-Hodgkin's lymphoma.
@en
P2093
A L Ervin-Haynes
C B Reeder
D Pietronigro
J A Polikoff
M S Czuczman
P L Zinzani
R Bouabdallah
P2860
P304
P356
10.1093/ANNONC/MDQ626
P577
2011-01-12T00:00:00Z